Results 121 to 130 of about 1,692 (164)
Mayo Clinic Proceedings, 2010 Vulvovaginal atrophy (VVA) is a common and underreported condition associated with decreased estrogenization of the vaginal tissue. Symptoms include dryness, irritation, soreness, and dyspareunia with urinary frequency, urgency, and urge incontinence. It can occur at any time in a woman's life cycle, although more commonly in the postmenopausal phase ...
Deborah Rhodes, Lynne T Shuster
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Sequential treatment in vulvovaginal atrophy
Climacteric, 2023Vulvovaginal atrophy (VVA) is a chronic and progressive disease that affects sexuality and quality of life. VVA is preventable and treatable, but requires long-term and often sequential treatment. Sequential treatment consists of designing a strategy that uses one or more medications for a long enough time to achieve the desired benefits with minimal ...
Santiago Palacios
exaly +3 more sources
Vulvovaginal atrophy in women after cancer
Climacteric, 2019The number of women surviving longer after a cancer diagnosis is increasing. This means that more awareness regarding their health is required. This review will focus on vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause, one of the most distressing adverse iatrogenic effects of the menopause, secondary to cancer therapies.
Nick Panay
exaly +3 more sources
Vulvovaginal atrophy – a tale of neglect
Climacteric, 2014The impact of vulvovaginal atrophy (VVA) on quality of life continues to be underestimated according to an expert review published in this issue of Climacteric1.
Nick, Panay, Anna, Fenton
openaire +2 more sources
Ospemifene in the Treatment of Vulvovaginal Atrophy
Annals of Pharmacotherapy, 2014Objective: To review the pharmacology, efficacy, and safety of ospemifene in the management of dyspareunia. Data Sources: Literature was sought using PubMed (1966-January 2014) and EMBASE (1973-January 2014). Search terms included ospemifene, FC-1271a, dyspareunia, vulvovaginal atrophy, and vaginal atrophy.
Kylie N, Barnes +3 more
openaire +2 more sources
Ospemifene, vulvovaginal atrophy, and breast cancer
Maturitas, 2013The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and ...
Gregory T, Wurz +2 more
openaire +2 more sources
New developments in the management of vulvovaginal atrophy: a comprehensive overview
Expert Opinion on Pharmacotherapy, 2023Proper recognition and individualized therapy of vulvovaginal atrophy (VVA) is paramount.Assessment of VVA should be performed using several questionnaires in combination with wet mount microscopy to determine Vaginal Cell Maturation Index (VCMI) and infections.
Donders, Gilbert G.G. +1 more
openaire +3 more sources
Advances in the treatment of vulvovaginal atrophy
Expert Review of Obstetrics & Gynecology, 2013Vulvovaginal atrophy is a frequently neglected symptom of menopause. While an estimated 10–40% of women are affected by the progressive symptoms of vaginal dryness, irritation, itching, dysuria and dyspareunia, only a quarter of symptomatic women are believed to seek medical attention. Until recently, treatments for vulvovaginal atrophy were limited to
Jill M Krapf +2 more
openaire +1 more source
Injection Treatments for Vulvovaginal Atrophy of Menopause: A Systematic Review
Aesthetic Plastic Surgery, 2023Injection treatments have been proposed as novel treatment options for Vulvovaginal Atrophy of Menopause (VVA) also known as Genitourinary Syndrome of Menopause (GSM). However, to date data about these treatments are poor.To assess all available injection treatments for VVA.A systematic review was performed by searching five electronic databases for ...
Moccia, Felice +5 more
openaire +4 more sources